Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; Department of Hematology, Pitié Salpêtrière Hospital, Pierre and Marie Curie University, UPMC GRC11-GRECHY, Paris, France; Division of Hematology, Department of Medicine at Huddinge, Karolinska Institute and University Hospital, Stockholm, Sweden; Division of Hematology and Hemostaseology, Department of Internal Medicine I, Vienna General Hospital, Vienna, Austria; Department of Hematology, Academic Medical Center; LYMMCARE (Lymphoma and Myeloma Center Amsterdam), Amsterdam, The Netherlands; Department of Haematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy; Comprehensive Cancer Center Ulm, Institute of Experimental Cancer Research, University Hospital Ulm, Ulm, Germany

[1]  M. Dimopoulos,et al.  Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy , 2015, Haematologica.

[2]  M. Dimopoulos,et al.  Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study. , 2015, Blood.

[3]  S. Treon,et al.  MYD88 Mutations and Response to Ibrutinib in Waldenström's Macroglobulinemia. , 2015, The New England journal of medicine.

[4]  S. Treon,et al.  Incidence of secondary malignancies among patients with Waldenström macroglobulinemia: An analysis of the SEER database , 2015, Cancer.

[5]  R. Advani,et al.  Ibrutinib in previously treated Waldenström's macroglobulinemia. , 2015, The New England journal of medicine.

[6]  B. Quesnel,et al.  MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome , 2014, British journal of haematology.

[7]  S. Treon,et al.  Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia. , 2014, Blood.

[8]  J. Miguel,et al.  Multiparameter flow cytometry for the identification of the Waldenström’s clone in IgM-MGUS and Waldenström’s Macroglobulinemia: new criteria for differential diagnosis and risk stratification , 2014, Leukemia.

[9]  J. Veldink,et al.  Association of IgM monoclonal gammopathy with progressive muscular atrophy and multifocal motor neuropathy: a case–control study , 2014, Journal of Neurology.

[10]  N. Lindeman,et al.  Detection Of MYD88 L265P In Peripheral Blood Of Patients With Waldenström's Macroglobulinemia and IgM Monoclonal Gammopathy Of Undetermined Significance , 2013 .

[11]  M. Stauch,et al.  Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial , 2013, The Lancet.

[12]  C. Buske,et al.  How to manage Waldenstrom's macroglobulinemia , 2013, Leukemia.

[13]  S. Chevret,et al.  Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  E. Kimby,et al.  Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop , 2013, British journal of haematology.

[15]  S. Treon,et al.  Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia. , 2012, Clinical lymphoma, myeloma & leukemia.

[16]  N. Harris,et al.  MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. , 2012, The New England journal of medicine.

[17]  T. Therneau,et al.  Progression in smoldering Waldenstrom macroglobulinemia: long-term results. , 2012, Blood.

[18]  D. Norris,et al.  Immunosuppression-Associated Pathology associated lymphoproliferative disorders were observed and entered into the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2012 .

[19]  S. Treon,et al.  Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab‐containing regimen , 2011, British journal of haematology.

[20]  I. Ghobrial,et al.  The role of 18F‐FDG PET/CT imaging in Waldenstrom macroglobulinemia , 2011, American journal of hematology.

[21]  N. Schmitz,et al.  Allogeneic stem-cell transplantation in patients with Waldenström macroglobulinemia: report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  T. Habermann,et al.  Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. , 2010, Mayo Clinic proceedings.

[23]  P. Richardson,et al.  Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia , 2010, American journal of hematology.

[24]  N. Schmitz,et al.  High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  D. Esseltine,et al.  Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  E. Ryu,et al.  Quantitation of serum monoclonal proteins: relationship between agarose gel electrophoresis and immunonephelometry. , 2009, Clinical chemistry.

[27]  S. Treon.  How I treat Waldenström macroglobulinemia. , 2009, Blood.

[28]  J. Crowley,et al.  International prognostic scoring system for Waldenstrom macroglobulinemia. , 2009, Blood.

[29]  E. Eisenhauer,et al.  Bortezomib in relapsed or refractory Waldenström's macroglobulinemia. , 2009, Clinical lymphoma & myeloma.

[30]  S. Treon,et al.  Ophthalmologic techniques to assess the severity of hyperviscosity syndrome and the effect of plasmapheresis in patients with Waldenström's macroglobulinemia. , 2009, Clinical lymphoma & myeloma.

[31]  S. Treon,et al.  Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  E. Kimby,et al.  Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  W. Klapper,et al.  The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG) , 2009, Leukemia.

[34]  G. Mead,et al.  Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[35]  M. Björkholm,et al.  Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden. , 2008, Blood.

[36]  H. Møller,et al.  The incidence and survival of Waldenström's Macroglobulinaemia in South East England. , 2008, Leukemia research.

[37]  M. Dimopoulos,et al.  Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  R. Advani,et al.  Multicenter Clinical Trial of Bortezomib in Relapsed/Refractory Waldenstrom's Macroglobulinemia: Results of WMCTG Trial 03-248 , 2007, Clinical Cancer Research.

[39]  A. Pestronk,et al.  Peripheral neuropathies in Waldenström’s macroglobulinaemia , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[40]  C. Lee,et al.  Characterization of familial Waldenstrom's macroglobulinemia. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  P. Gobbi,et al.  Prognostic Validation of the International Classification of Immunoglobulin M Gammopathies: A Survival Advantage for Patients with Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance? , 2005, Clinical Cancer Research.

[42]  M. Rue,et al.  Initial immunoglobulin M ‘flare’ after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia , 2004, Cancer.

[43]  S. Treon,et al.  Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[44]  M. McMaster.  Familial Waldenstrom's macroglobulinemia. , 2003, Seminars in oncology.

[45]  M. Dimopoulos,et al.  Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. , 2003, Seminars in oncology.

[46]  T. Lister,et al.  Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. , 2003, Seminars in oncology.

[47]  M. Dimopoulos,et al.  Treatment of Waldenström's macroglobulinemia with rituximab. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  S. Montoto,et al.  Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases , 2001, British journal of haematology.

[49]  C. Dykewicz.  Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[50]  J. Fraumeni,et al.  Waldenström's macroglobulinemia , 1998, Cancer.